Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,252 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Head Clear all
Completed Phase 1Phase 2 Interventional Results available

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT04432597
View directory record Official record
Conditions
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer, Cervical Cancer
Interventions
PRGN-2009, M7824, EKG, CT Scan, Brain MRI, Biopsy
Biological · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 19, 2026, 1:05 PM EDT
Terminated No phase listed Observational

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

NCT06549413
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Phase 2 Interventional

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

NCT00968435
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
bevacizumab, cisplatin, cetuximab, radiation therapy
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Phase 1 Interventional Results available

Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017
View directory record Official record
Conditions
Advanced Solid Tumors, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Renal Cell Carcinoma, Malignant Glioma, Non-small Cell Lung Cancer
Interventions
Cabiralizumab, Nivolumab
Biological
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
39
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 19, 2026, 1:05 PM EDT
Not listed Not applicable Interventional

FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer

NCT00983697
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
therapeutic conventional surgery, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Safety Harbor, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 19, 2026, 1:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time

NCT01342978
View directory record Official record
Conditions
Oropharyngeal Cancer, Human Papillomavirus
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1

NCT02844543
View directory record Official record
Conditions
Eye-tracking
Interventions
EYE-SYNC eye-tracking device, SCAT-3, Desktop Eye-Tracker
Device · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 25 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 19, 2026, 1:05 PM EDT
Completed No phase listed Observational

The 2021-2022 Study of Family and Staff Well-Being in Head Start FACES Programs

NCT06512740
View directory record Official record
Conditions
Head Start Participation
Interventions
Not listed
Lead sponsor
Mathematica Policy Research, Inc.
Other
Eligibility
2 Years and older
Enrollment
4,825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00002774
View directory record Official record
Conditions
Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions
Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
17 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 19, 2026, 1:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Field Implementation of iDETECT

NCT02529618
View directory record Official record
Conditions
Concussion, Brain Trauma
Interventions
integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT), Riddell High Impact Technology (HIT) System, i1 Biometrics Vector Mouth Guard
Device
Lead sponsor
Emory University
Other
Eligibility
14 Years and older
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • College Park, Georgia • Marietta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 19, 2026, 1:05 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

NCT05877430
View directory record Official record
Conditions
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer
Interventions
CJRB-101, Pembrolizumab injection
Drug
Lead sponsor
CJ Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Irvine, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 19, 2026, 1:05 PM EDT
Recruiting Phase 2 Interventional

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient-Reported Xerostomia

NCT07278557
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
MRI sialography, Parotid Duct Sparing Radiation Therapy Planning, Parotid Sparing Radiation Therapy Planning
Device · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 1:05 PM EDT
Active, not recruiting Phase 2 Interventional

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

NCT03942653
View directory record Official record
Conditions
Salivary Gland Carcinoma
Interventions
Goserelin Acetate, Pembrolizumab
Drug
Lead sponsor
Manish Patel
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 1:05 PM EDT
Terminated Phase 1 Interventional

Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT02438995
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
Interventions
Intraarterial Cetxuimab (Erbitux)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evidence-based Intervention for Improved Head Impact Safety in Youth Football - Aim 1 and Aim 3

NCT04908930
View directory record Official record
Conditions
Head Injury, Sport Injury
Interventions
On-field activity group - Aim 3
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
11 Years to 14 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Phase 1 Interventional

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

NCT03565445
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ASP1948, nivolumab, pembrolizumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
New Haven, Connecticut • Louisville, Kentucky • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

NCT02799095
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ALKS 4230, ALKS 4230 + pembrolizumab
Drug
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
12
States / cities
Denver, Colorado • Port Saint Lucie, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Phase 2 Interventional Results available

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer

NCT00711412
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine, Combination Therapy - Oxaliplatin, Combination Therapy - Radiation, Evaluation for response and surgery
Drug · Radiation · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 19, 2026, 1:05 PM EDT
Completed No phase listed Observational

Optimization of MRI for Radiation Therapy

NCT02045381
View directory record Official record
Conditions
Cancer Liver, Cancer Brain, Cancer Head &Neck, Cancer Pelvis
Interventions
MRI Group
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 19, 2026, 1:05 PM EDT
Not yet recruiting Not applicable Interventional

Combination iSTAT/Alinity and IR Oculography for Head CT Necessity and Recovery Prediction After mTBI

NCT07094230
View directory record Official record
Conditions
Blood
Interventions
biomarkers analyses
Diagnostic Test
Lead sponsor
Captain James A. Lovell Federal Health Care Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 19, 2026, 1:05 PM EDT
Terminated Phase 2 Interventional Results available

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

NCT05101798
View directory record Official record
Conditions
Neoplasm, Skull Base Neoplasm
Interventions
5-Aminolevulinic acid Hydrochloride
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 19, 2026, 1:05 PM EDT
Completed Not applicable Interventional

SpeakFree Heat and Moisture Exchanger (HME)

NCT05349487
View directory record Official record
Conditions
Laryngeal Cancer, Laryngectomy
Interventions
SpeakFree HME Hands Free Valve, Digital Occlusion, Digital Depression HME
Device · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 19, 2026, 1:05 PM EDT
Completed No phase listed Observational

Thyroid Dysfunction in Head and Neck Surgery Patients

NCT00592514
View directory record Official record
Conditions
Thyroid Dysfunction
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 19, 2026, 1:05 PM EDT
Terminated Phase 1 Interventional

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

NCT04348916
View directory record Official record
Conditions
Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
Interventions
ONCR-177, pembrolizumab
Biological
Lead sponsor
Oncorus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Duarte, California • Denver, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 19, 2026, 1:05 PM EDT